Geron Corporation Stock News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,000 shares o...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigat...

LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK , May 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), of the important May 12, 2025 lead plaintiff deadline. So what: If you purchased Geron securities during the Class Period you may be entitled...

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / If you purchased or acquired securities in Geron between June 7, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...

Geron's RYTELO faces limited revenue potential in a crowded MDS market, with predominantly 3L+ utilization and flat sequential growth. Despite a narrowed net loss, Geron remains unprofitable with no clear path to cash generation and faces increasing operating expenses. Imetelstat's prospects in MF are poor against established treatments, and its clinical and market challenges are significant.

Shares of commercial-stage biotech Geron (GERN) couldn't quite surmount the hump of Hump Day. After the company released its latest set of quarterly figures, its stock price wobbled as investors determined how best to digest the results.

Geron Corporation (NASDAQ:GERN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Ron Maldiver - Investor Relations Dawn Bir - Interim President and Chief Executive Officer Michelle Robertson - Chief Financial Officer Jim Ziegler - Chief Commercial Officer Joseph Eid - Executive Vice President of Research and Development Conference Call Participants Tara Bancroft - T...